Office of Research & Development |
  |
Prostate cancer occurs in the prostate, a walnut-sized gland that sits at the base of the bladder and is part of the male reproductive system. About one in eight men will be diagnosed with prostate cancer at some point in their lifetime. Prostate cancer is the most commonly diagnosed cancer among U.S. Veterans, making up 30% of new cancer diagnoses in the VA.
In 2016, VA Research partnered with the Prostate Cancer Foundation to establish the Precision Oncology Program for Cancer of the Prostate (POPCaP). The program uses genetic information to tailor individualized treatments for Veterans with advanced prostate cancer. Components of POPCaP include access to genetic testing and counseling, prostate cancer clinical trials, and FDA-approved drugs targeted to specific cancer mutations.
|
Precision Oncology Centers of Excellence |
Facility |
Principal Investigator |
|
The Stephen J. Cloobeck Precision Oncology Center of Excellence |
VA Puget Sound Health Care System Seattle, WA |
Bruce Montgomery |
|
The Michael and Lori Milken Family Foundation Precision Oncology Center of Excellence |
Greater Los Angeles VA Medical Center Los Angeles, CA |
Matthew Rettig |
|
The Robert Frederick Smith Precision Oncology Center of Excellence |
Jesse Brown VA Medical Center Chicago, IL |
Joshua Meeks |
|
The Stewart J. Rahr Foundation Precision Oncology Center of Excellence |
Ann Arbor VA Medical Center Ann Arbor, MI |
Phoebe Tsao |
|
The John and Daria Barry Foundation Precision Oncology Center of Excellence |
Manhattan VA Medical Center Manhattan, NY |
Danil Makarov |
|
The Blavatnik Family Foundation Precision Oncology Center of Excellence |
James J. Peters VA Medical Center Bronx, NY |
Antonio Fojo |
|
The Jonathan and Plum Simons Precision Oncology Center of Excellence |
Corporal Michael J. Crescenz VA Medical Center Philadelphia, PA |
Kyle Robinson Nevena Damjanov |
|
Prostate Cancer Foundation Precision Oncology Center of Excellence |
Durham VA Medical Center Durham, NC |
Rhonda Bitting |
|
The Edward P. Evans Foundation Precision Oncology Center of Excellence |
Washington VA Medical Center Washington, DC |
Manish Jain |
|
The John and Daria Barry Foundation Precision Oncology Center of Excellence |
James A. Haley Veterans Hospital Tampa, FL Bay Pines VA Medical Center Bay Pines, FL |
Kosj Yamoah |
|
Portland VA Medical Center Portland, OR |
Julie Graff |
|
|
Jamaica Plain VA Medical Center Boston, MA |
Chong-Xian Pan |
|
|
San Francisco VA Medical Center San Francisco, CA |
Franklin Huang |
|
|
Baltimore VA Medical Center Baltimore, MD |
Arif Hussain |
|
|
Atlanta VA Medical Center Atlanta, GA |
Wayne Harris Maria Ribeiro |
|
|
Ralph H. Johnson VA Medical Center Charleston, SC |
Steven Savage |
|
|
Rocky Mountain Regional VA Medical Center Denver, CO |
Daniel Bowles |
|
|
Michael E. DeBakey VA Medical Center Houston, TX |
Anita Sabichi |
|
|
Kansas City VA Medical Center Kansas City, MO |
Linda Verkruyse |
|
|
John J. Cochran Veterans Hospital St. Louis, MO |
Eric Knoche |
In support of the POPCaP program, VA launched the PATCH initiative—Prostate Cancer Analysis for Therapy Choice. This effort will increase the number of VHA facilities involved in prostate cancer clinical trials, increase Veteran participation in precision medicine studies, and grow the number of physicians providing care for prostate cancer patients and conducting prostate cancer research.
View Studies
|
Acronym |
Study Title |
Status |
Locations |
|
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer |
Recruiting |
Charleston, Durham, Los Angeles, Manhattan, Philadephia, Portland, Puget Sound, St. Louis |
|
|
High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency |
Recruiting |
Atlanta, Charleston, Connecticut, Denver, Durham, Gainesville, Houston, Kansas City, Louisville, Orlando, Portland, Puget Sound, St. Louis |
|
|
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation |
Recruiting |
Ann Arbor, Bay Pines, Bronx, Chicago, Durham, Los Angeles, New York, Philadelphia, Portland, Puget Sound, Richmond, San Francisco, Washington DC |
|
|
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA) |
Recruiting |
Ann Arbor, Atlanta, Aurora, CO, Bay Pines, Boise, Bronx, Chicago, Durham, Kansas City, Los Angeles, Madison, WI, Minneapolis, New York, Orlando, Philadelphia, Portland, Puget Sound, San Juan PR, Washington DC |
|
|
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer |
Recruiting |
Ann Arbor (pending), Atlanta (pending), Portland, San Francisco |
|
|
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) |
Recruiting |
Currently in site selection phase |
|
|
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC |
Recruiting |
Ann Arbor, Los Angeles, St. Louis, Washington DC |
|
|
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (leuprolide and abiraterone acetate) in Combination with AKT Inhibition (capivasertib) for High-Risk Localized Prostate Cancer with PTEN Loss |
Start Up |
Bronx, Portland, Puget Sound, San Antonio, |
|
|
Copper Cu64 PSMA I&T Injection in Patients with Histologically Proven Metastatic Prostate Cancer |
Active, not recruiting |
Currently collecting site information |
|
|
Study Evaluating Metastatic Castrate Resistant Prostate Cancer Using 177lu-Pnt2002 PSMA Therapy After Second Line Hormonal Treatment |
Recruiting |
Ann Arbor, Dallas, Houston, Los Angeles, Nashville, New York, Palo Alto, Philadelphia, Puget Sound, St. Louis, Tampa, Vancouver |
|
|
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer |
Recruiting |
Currently collecting site information |
|
|
A Phase 2/3, Randomized, Open-label, Study of MGC018 Versus Androgen Receptor Axis-targeted Therapy (Abiraterone or Enzalutamide) in Participants with Metastatic Castration-resistant Prostate Cancer |
Start Up |
Aurora, CO, Baltimore, Charleston, Kansas City, Portland, San Francisco |
|
|
A Phase 2 Randomized Study of YONSA® (Abiraterone Acetate), Enzalutamide or Apalutamide as First Line Therapy in Veterans With Castrate-sensitive Prostate Cancer |
Start Up |
Ann Arbor, Bay Pines, Boston, Bronx, Chicago, Houston, Los Angeles, Montrose, NY, New York, Philadelphia, Portland, Puget Sound, Salisbury, NC, San Francisco, St. Louis, Tampa, Washington DC |
Eighty-five percent of men with prostate cancer have disease contained within the prostate gland itself. However, 20% of Veterans who undergo local therapy (radiation or surgery) will see their cancer return and spread outside the prostate.
Scientists now understand that prostate cancer can spread beyond the prostate itself, yet not disperse widely throughout the body. Evidence suggests that adding radiation or surgery that targets areas of cancer spread to standard systemic treatment (SST) for prostate cancer may be an effective treatment.
The STARPORT clinical trial (STAndard Systemic TheRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer) is examining the benefits of local cancer therapy combined with SST to treat prostate cancer with limited spread. Researchers want to find out if this combination improves disease control compared to SST alone in Veterans with recurrent prostate cancer.
